EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real‐world study

Cathrine E Gjerulfsen iD, Marina Nikanorova, Kern Olofsson, Cecilie Johannessen Landmark iD, Guido Rubboli iD, Rikke S Møller iD

Epilepsia Open · 2024

DOI: 10.1002/epi4.13029 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsia Open, 2024. Verfasst von Cathrine E Gjerulfsen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (Member of ERN EpiCARE), Dianalund, Denmark. Hauptthemen laut MEDLINE: Fenfluramine, Epilepsies, Myoclonic, Health Care Costs, Seizures. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Dravet syndrome is a developmental and epileptic encephalopathy characterized by early onset epilepsy with multiple seizure types often intractable to treatment. Randomized clinical trials have demonstrated how treatment with fenfluramine significantly reduces seizure frequency in patients with Dravet syndrome. The study aims to (1) describe the efficacy and tolerability of fenfluramine in a Danish cohort of patients with Dravet syndrome; and (2) evaluate whether treatment with fenfluramine reduces epilepsy‐related hospital contacts administrated by pediatricians or epilepsy‐trained nurses.

Methods

A retrospective registry‐based cohort study at the Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark, enrolled 30 pediatric patients with Dravet syndrome treated with fenfluramine between 2017 and 2023.

Results

Thirty patients with Dravet syndrome (aged 3–21 years, 12 females) with a verified pathogenic SCN1A variant were included. They were treated with fenfluramine at a mean duration of 29 months with a mean maintenance dose of 0.5 mg/kg/day. The number of patient‐years on treatment was 75 years. At last follow‐up, 6 patients had discontinued treatment due to lack of efficacy or adverse effects. In the remaining 24 patients, generalized tonic–clonic seizures were reduced by ≥30% in 83%, by ≥50% in 67%, and by 100% in 25%. Additionally, 71% of the patients were reduced in concomitant anti‐seizure medication, and 75% experienced a reduction (mean reduction at 52%, range 11%–94%) in epilepsy‐related hospital contacts from baseline to the end of the treatment period. Significance Treatment with fenfluramine effectively reduced seizure frequency and concomitant antiseizure medication in patients with Dravet syndrome. Furthermore, a decrease in epilepsy‐related contacts by 80% was observed over 6 years of treatment, which may indicate cost‐effective benefits. Plain Language Summary Patients with Dravet syndrome suffer from severe epileptic seizures that are difficult to treat with medication. Earlier, treatment with fenfluramine (an anti‐seizure medication) has been documented to decrease the total number of seizures in patients with Dravet syndrome. This publication summarizes the experiences with fenfluramine in children with Dravet syndrome at the Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark. Our publication also illustrates that treatment with fenfluramine may reduce the patients' number of yearly contacts with doctors and nurses specialized in epilepsy treatment, which may indicate cost‐effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenfluramineEpilepsies, MyoclonicHealth Care CostsSeizuresHumansFemaleMaleChildRetrospective StudiesAdolescentChild, PreschoolYoung AdultDenmarkAnticonvulsantsSelective Serotonin Reuptake InhibitorsRegistriesTreatment Outcome

Stichwörter der Autor:innen

SCN1Achildhood epilepsyconvulsive seizurespersonalized medicine

Substanzen

FenfluramineAnticonvulsantsSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, Filadelfia (Member of ERN EpiCARE), Dianalund, Denmark.
  • Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
  • Department of Child Neurology, Danish Epilepsy Centre, Dianalund, Denmark.
  • Department of Pharmacy, Oslo Metropolitan University (Member of the ERN EpiCare), Oslo, Norway.
  • The National Center for Epilepsy, Oslo University Hospital, Oslo, Norway.
  • Department of Pharmacology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Cathrine E Gjerulfsen, Cecilie Johannessen Landmark, Guido Rubboli, Rikke S Møller

Förderung

  • UCB

Zitieren

APA

Gjerulfsen, C. E., Nikanorova, M., Olofsson, K., Johannessen Landmark, C., Rubboli, G., & Møller, R. S. (2024). Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real‐world study. Epilepsia Open. https://doi.org/10.1002/epi4.13029

Vancouver

Gjerulfsen CE, Nikanorova M, Olofsson K, Johannessen Landmark C, Rubboli G, Møller RS. Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real‐world study. Epilepsia Open. 2024. doi:10.1002/epi4.13029

BibTeX
@article{Gjerulfsen2024,
  author = {Gjerulfsen, Cathrine E and Nikanorova, Marina and Olofsson, Kern and Johannessen Landmark, Cecilie and Rubboli, Guido and Møller, Rikke S},
  title = {Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real‐world study},
  journal = {Epilepsia Open},
  year = {2024},
  doi = {10.1002/epi4.13029}
}
Kostenlos starten →